Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BARDA

Despite RFK Jr’s hesitancy the HHS is quietly looking at developing two new vaccines

The vaccines are intended to be developed for use against Marburg virus and Sudan ebolavirus, two hemorrhagic fevers in the same family as the Ebola virus

The Independent UK

Trump betting on old vaccine tech

It's in sharp contrast to Operation Warp Speed, which led to the creation of the COVID vaccines

Salon

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Bird flu vaccines face a problem: eggs

Fertilized hen eggs are still the main ingredient in making vaccines that may protect us against H5N1

Salon

Superman, Wonder Woman, Batman, and all of DC's April 2024 Solicitations

It's no April Fool - DC's full April 2024 solicitations have arrived

GamesRadar

1 Penny Stock Insiders Are Buying with Both Hands

This 'Strong Buy'-rated penny stock has scored some major insider buying from C-suite insiders. Here's what investors need to know about this small-cap healthcare stock.

Barchart

The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It

Vir Biotechnology inked a deal Tuesday worth up to $1 billion for its experimental flu treatment, leading Vir stock to surge.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

T2 Biosystems Shares Slide As Interim Q2 Sales Trail Consensus

T2 Biosystems Inc (NASDAQ:TTOO) expects Q2 FY22 revenues of $5.8 million - $6.1 million, below the consensus of $6.87 million. The interim numbers include product revenue of $2.5 million - $2.7 million and research revenue of $3.3 million - $3.4 million. Executed contracts for 12 T2Dx Instruments during Q2, consisting of 6…

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

CFRX: Results from Interim Futility Analysis in July 2022…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Details Of Revive Therapeutics' Update On Bucillamine Phase 3 Trial For COVID Treatment

Revive Therapeutics (OTC: RVVTF) has provided an update on Phase 3 of its Buc

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract

In its SEC filing, Chimerix Inc (NASDAQ:CMRX) announced that it had been aware of unusual trading activity in the Company's common stock. The Company believes the unusual trading activity may be attributable to statements regarding smallpox antiviral development and procurement contained in the Fiscal Year 2023 Congressional Justification for the Public Health…

Benzinga

T2 Biosystems Secures Additional BARDA Funding To Develop Blood Test Panels To Detect Sepsis-Causing Pathogens

The Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems Inc (NASDAQ:TTOO) If all contract options are exercised, the total potential BARDA funding is $69.0 million. The additional funding will be used to advance the U.S. clinical trials for…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

AVITA Medical Modifies BARDA Contract For RECELL System In Soft Tissue Reconstruction

Biomedical Advanced Research and Development Authority (BARDA) has

Benzinga

MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission

The Biomedical Advanced Research and Development Authority (BARDA) will

Benzinga

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

The Biomedical Advanced Research and Development Authority (BARDA) will

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.